Format

Send to

Choose Destination
Brachytherapy. 2011 Nov-Dec;10(6):503-7. doi: 10.1016/j.brachy.2011.01.013. Epub 2011 Mar 9.

Palladium-103 eye plaque brachytherapy for primary adenocarcinoma of the ciliary body epithelium.

Author information

1
The New York Eye Cancer Center, New York City, NY 10065, USA. pfinger@eyecancer.com

Abstract

PURPOSE:

To present an interventional case report on the use of plaque brachytherapy for adenocarcinoma of the nonpigmented ciliary epithelium.

METHODS AND MATERIALS:

A 36-year-old woman with unilateral right eye pain and finger counting vision was noted to have an anterior segment intraocular mass. It extended between the iris and lens and into the pupillary aperture. High-frequency ultrasound imaging revealed a ciliary body origin. A minimally invasive biopsy technique allowed for a cytology and histopathology diagnosis of primary adenocarcinoma of the ciliary epithelium. Treatment was performed with palladium-103 ophthalmic plaque brachytherapy (80-Gy apex). Main outcome measures include visual acuity, local control, radiation complications, and metastatic disease.

RESULTS:

The patient presented with counting fingers vision, focal angle closure, cataract, and a 5.5-mm thick ciliary body malignancy. At 3 years after radiation therapy and 2.5 years after cataract extraction, her visual acuity was improved to 20/30 and the tumor residua stabilized at 60% of its initial thickness. There has been neither radiation-related keratopathy, retinopathy, optic neuropathy nor metastatic disease.

CONCLUSIONS:

Plaque brachytherapy was used to treat primary adenocarcinoma of the ciliary epithelium. With 3-year followup, there has been excellent local control, preservation of the eye, and recovery of vision.

PMID:
21393069
DOI:
10.1016/j.brachy.2011.01.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center